Literature DB >> 2824807

Site-specific mutations at a picornavirus VP3/VP1 cleavage site disrupt in vitro processing and assembly of capsid precursors.

G D Parks1, A C Palmenberg.   

Abstract

Most proteolytic cleavages within the picornavirus polyproteins are carried out by viral protease 3C. For encephalomyocarditis virus, the protease 3C-catalyzed processing occurs between Gln-Gly or Gln-Ser amino acid pairs which are flanked by proline residues, but the sequence-specific constraints on recognition and cleavage by the enzyme are not completely understood. To examine alternative cleavage site sequences, we constructed a cDNA plasmid which expresses the viral L-P1-2A capsid precursor in vitro and introduced site-specific mutations into the Gln-Gly pair at the VP3/VP1 junction. The altered protein substrates were tested for cleavage activity in assays with protease 3C. The encephalomyocarditis virus 3C processed Gln-Ala as efficiently as its natural sites but did not cleave Gln-Val, Gln-Glu, Lys-Gly, Lys-Ala, Lys-Val, Lys-Glu, or Pro-Gly combinations. Displacement of the flanking proline residue by an engineered insertion slowed but did not prevent cleavage at this site. Also, a mutant defective in processing at the VP3/VP1 junction was unable to form 14S pentameric assembly intermediates in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824807      PMCID: PMC255979          DOI: 10.1128/JVI.61.12.3680-3687.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Translation of encephalomyocarditis virus RNA in reticulocyte lysates: kinetic analysis of the formation of virion proteins and a protein required for processing.

Authors:  D S Shih; C T Shih; D Zimmern; R R Rueckert; P Kaesberg
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

2.  Protease required for processing picornaviral coat protein resides in the viral replicase gene.

Authors:  A C Palmenberg; M A Pallansch; R R Rueckert
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

3.  In vitro molecular genetics as a tool for determining the differential cleavage specificities of the poliovirus 3C proteinase.

Authors:  M F Ypma-Wong; B L Semler
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

Review 4.  Serine proteases: structure and mechanism of catalysis.

Authors:  J Kraut
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

5.  Further evidence on the formation of poliovirus proteins.

Authors:  M F Jacobson; J Asso; D Baltimore
Journal:  J Mol Biol       Date:  1970-05-14       Impact factor: 5.469

6.  Cleavage of the capsid protein precursors of encephalomyocarditis virus in rabbit reticulocyte lysates.

Authors:  C Y Shih; D S Shih
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

7.  Preparation and characterization of encephalomyocarditis (EMC) virus.

Authors:  R R Rueckert; M A Pallansch
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

8.  In vitro synthesis and assembly of picornaviral capsid intermediate structures.

Authors:  A C Palmenberg
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

9.  Evidence for intramolecular self-cleavage of picornaviral replicase precursors.

Authors:  A C Palmenberg; R R Rueckert
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

10.  Proteolytic processing of poliovirus polypeptides: antibodies to polypeptide P3-7c inhibit cleavage at glutamine-glycine pairs.

Authors:  R Hanecak; B L Semler; C W Anderson; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

View more
  16 in total

1.  RNA binding properties of poliovirus subviral particles.

Authors:  C I Nugent; K Kirkegaard
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

2.  Mutational analysis of the encephalomyocarditis virus primary cleavage.

Authors:  H Hahn; A C Palmenberg
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  Cleavage site mutations in the encephalomyocarditis virus P3 region lethally abrogate the normal processing cascade.

Authors:  D J Hall; A C Palmenberg
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  A rapid method for determination of endoproteinase substrate specificity: specificity of the 3C proteinase from hepatitis A virus.

Authors:  J R Petithory; F R Masiarz; J F Kirsch; D V Santi; B A Malcolm
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Theiler's murine encephalomyelitis virus contrasts with encephalomyocarditis and foot-and-mouth disease viruses in its functional utilization of the StopGo non-standard translation mechanism.

Authors:  G Loughran; J E Libbey; S Uddowla; M F Scallan; M D Ryan; R S Fujinami; E Rieder; J F Atkins
Journal:  J Gen Virol       Date:  2012-10-24       Impact factor: 3.891

6.  Proteolytic cleavage of encephalomyocarditis virus capsid region substrates by precursors to the 3C enzyme.

Authors:  G D Parks; J C Baker; A C Palmenberg
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3.

Authors:  M M Falk; P R Grigera; I E Bergmann; A Zibert; G Multhaup; E Beck
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Conditional poliovirus mutants made by random deletion mutagenesis of infectious cDNA.

Authors:  K Kirkegaard; B Nelsen
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

9.  Mutational analysis of the EMCV 2A protein identifies a nuclear localization signal and an eIF4E binding site.

Authors:  Rachel Groppo; Bradley A Brown; Ann C Palmenberg
Journal:  Virology       Date:  2010-12-09       Impact factor: 3.616

10.  Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation.

Authors:  D C Ansardi; C D Morrow
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.